...
首页> 外文期刊>Journal of cataract and refractive surgery >Cataract surgery in patients with age-related macular degeneration. one-year outcomes.
【24h】

Cataract surgery in patients with age-related macular degeneration. one-year outcomes.

机译:白内障手术治疗与年龄有关的黄斑变性。一年的结果。

获取原文
获取原文并翻译 | 示例

摘要

To determine whether patients with age-related macular degeneration (ARMD) benefit from cataract surgery and to assess the risk of progression of preexisting maculopathy 4 and 12 months postoperatively.Princess Alexandra Eye Pavilion, Royal Infirmary of Edinburgh, Edinburgh, Scotland.Two groups of patients were evaluated prospectively. The study group comprised patients with ARMD scheduled to have cataract surgery (n = 40). The control group comprised patients with ARMD not having cataract surgery (n = 43). Patients were assessed at baseline (preoperatively) and 4 and 12 months postoperatively. Assessment included visual function tests and quality of life (QoL) measures. The mean values for each item tested were obtained for each group at each visit, and comparisons between visits were done using the Wilcoxon signed rank test.There were significant benefits of cataract surgery in terms of visual function and QoL measures at 4 and 12 months. There was no increased risk of progression of maculopathy in the study group. There were no significant differences in the items tested in the control group.One year postoperatively, QoL benefits were maintained in the study group and there was no increased risk of progression of maculopathy in patients with mild and moderate degrees of ARMD. Larger numbers of patients must be assessed prospectively for longer periods to determine the relative risk of progression of different stages of ARMD after cataract surgery.
机译:为了确定年龄相关性黄斑变性(ARMD)患者是否从白内障手术中受益并评估术后4到12个月内已有黄斑病变进展的风险,苏格兰爱丁堡爱丁堡皇家医院亚历山大亚历山大眼馆,两组对患者进行前瞻性评估。研究组包括计划进行白内障手术的ARMD患者(n = 40)。对照组包括未经白内障手术的ARMD患者(n = 43)。在基线(术前)以及术后4和12个月对患者进行评估。评估包括视觉功能测试和生活质量(QoL)措施。在每次访视时获得每个组每个被测项目的平均值,并使用Wilcoxon符号等级检验进行访视之间的比较。在4个月和12个月时,白内障手术在视觉功能和QoL措施方面具有显着优势。在研究组中,黄斑病变进展的风险没有增加。对照组的测试项目没有显着差异。术后一年,研究组维持QoL获益,轻度和中度ARMD患者的黄斑病变进展风险没有增加。必须对更多的患者进行前瞻性评估,以确定更长时间,以确定白内障手术后不同阶段ARMD进展的相对风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号